Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer

In this analysis, we found that risk factors were most strongly associated enrolment in the IDEAL trial. In contrast, patient experiences were the most significant factors leading to early treatment discontinuation, with no effect on DFS.